NVCR
Novocure LtdNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$1.23B
P/E Ratio
—
EPS
$-1.27
Beta
0.82
52W High
$20.06
52W Low
$9.82
50-Day MA
$11.98
200-Day MA
$13.04
Dividend Yield
—
Profit Margin
-20.80%
Forward P/E
909.09
PEG Ratio
-0.47
About Novocure Ltd
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Fundamentals
| Revenue (TTM) | $655.35M |
| Gross Profit (TTM) | $490.18M |
| EBITDA | $-135.16M |
| Operating Margin | -21.30% |
| Return on Equity | -38.90% |
| Return on Assets | -9.06% |
| Revenue/Share (TTM) | $5.88 |
| Book Value | $3.03 |
| Price-to-Book | 3.46 |
| Price-to-Sales (TTM) | 1.87 |
| EV/Revenue | 1.495 |
| EV/EBITDA | -6.92 |
| Quarterly Earnings Growth (YoY) | -6.00% |
| Quarterly Revenue Growth (YoY) | 8.10% |
| Shares Outstanding | $113.79M |
| Float | $94.63M |
| % Insiders | 9.48% |
| % Institutions | 85.73% |
Analyst Ratings
Consensus ($25.07 target)
1
Strong Buy4
Buy2
HoldData last updated: 4/9/2026